Compare MDIA & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDIA | ECOR |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 50.0M |
| IPO Year | 2019 | 2018 |
| Metric | MDIA | ECOR |
|---|---|---|
| Price | $0.61 | $7.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 30.3K | ★ 44.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.00 | 53.51 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,571,000.00 | $25,182,000.00 |
| Revenue This Year | N/A | $28.92 |
| Revenue Next Year | N/A | $32.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 195.05 | 57.09 |
| 52 Week Low | $0.54 | $4.16 |
| 52 Week High | $1.60 | $15.67 |
| Indicator | MDIA | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 65.08 |
| Support Level | $0.56 | $4.64 |
| Resistance Level | $0.65 | $8.10 |
| Average True Range (ATR) | 0.04 | 0.69 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 78.96 | 93.02 |
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.